Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial

Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M. Glenn, Filip Dubovsky, Raburn M. Mallory the Novavax 2019nCoV-101 Study Group
doi: https://doi.org/10.1101/2022.11.18.22282414
Katia Alves
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce S Plested
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirley Galbiati
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gordon Chau
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shane Cloney-Clark
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhu Zhu
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raj Kalkeri
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nita Patel
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Smith
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Marcheschi
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Pfeiffer
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather McFall
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gale Smith
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory M. Glenn
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Filip Dubovsky
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raburn M. Mallory
Novavax, Inc., Gaithersburg, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: RMallory{at}novavax.com
Novavax, Inc., Gaithersburg, MD
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Article Information

doi 
https://doi.org/10.1101/2022.11.18.22282414
History 
  • November 20, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Katia Alves,
  2. Joyce S Plested,
  3. Shirley Galbiati,
  4. Gordon Chau,
  5. Shane Cloney-Clark,
  6. Mingzhu Zhu,
  7. Raj Kalkeri,
  8. Nita Patel,
  9. Kathy Smith,
  10. Alex Marcheschi,
  11. Susan Pfeiffer,
  12. Heather McFall,
  13. Gale Smith,
  14. Gregory M. Glenn,
  15. Filip Dubovsky,
  16. Raburn M. Mallory* and
  17. the Novavax 2019nCoV-101 Study Group
  1. Novavax, Inc., Gaithersburg, MD
  1. ↵*Correspondence to: Raburn M. Mallory, MD, Novavax, 21 Firstfield Rd., Gaithersburg, MD, 20878, RMallory{at}novavax.com; T: 240.661.6718
Back to top
PreviousNext
Posted November 20, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M. Glenn, Filip Dubovsky, Raburn M. Mallory
medRxiv 2022.11.18.22282414; doi: https://doi.org/10.1101/2022.11.18.22282414
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Immunogenicity and safety of a 4th homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2, randomized, placebo-controlled trial
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Mingzhu Zhu, Raj Kalkeri, Nita Patel, Kathy Smith, Alex Marcheschi, Susan Pfeiffer, Heather McFall, Gale Smith, Gregory M. Glenn, Filip Dubovsky, Raburn M. Mallory
medRxiv 2022.11.18.22282414; doi: https://doi.org/10.1101/2022.11.18.22282414

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)